Abstract:Gut microbiota is a complex system of organisms, mainly different bacterial species, the gut microbiota interacts with the host, affects host systems and organs (e.g. the brain) and modulates the host physiological functions. The interaction between the gut microbiota and the brain, famously known as gut‐brain axis is a bidirectional connection via neural, immune, and endocrine pathways.IntroductionObesity is a major health problem that is associated with many physiological and mental disorders, such as diabetes, stroke, and depression. Gut microbiota has been affirmed to interact with various organs, including the brain. Intestinal microbiota and their metabolites might target the brain directly via vagal stimulation or indirectly through immune‐neuroendocrine mechanisms, and they can regulate metabolism, adiposity, homoeostasis and energy balance, and central appetite and food reward signaling, which together have crucial roles in obesity. Studies support the concept of bidirectional signaling within the gut–brain axis (GBA) in the pathophysiology of obesity, mediated by metabolic, endocrine, neural, and immune system mechanisms.Materials and methodsScopus, PubMed, Google Scholar, and Web of Science databases were searched to find relevant studies.ResultsThe gut–brain axis (GBA), a bidirectional connection between the gut microbiota and brain, influences physiological function and behavior through three different pathways. Neural pathway mainly consists of the enteric nervous system (ENS) and vagus nerve. Endocrine pathway, however, affects the neuroendocrine system of the brain, particularly the hypothalamus–pituitary–adrenal (HPA) axis and immunological pathway. Several alterations in the gut microbiome can lead to obesity, by modulating metabolic pathways and eating behaviors of the host through GBA. Therefore, novel therapies targeting the gut microbiome, i.e., fecal microbiota transplantation and supplementation with probiotics and prebiotics, can be a potential treatment for obesity.ConclusionThis study corroborates the effect of gut microbiome on physiological function and body weight. The results show that the gut microbiota is becoming a target for new antiobesity therapies.

The Role of the Gut Microbiota in the Gut–Brain Axis in Obesity: Mechanisms and Future Implications

Microbiome–Gut Dissociation: Investigating the Origins of Obesity

The interaction between microbiome and host central nervous system: the gut-brain axis as a potential new therapeutic target in the treatment of obesity and cardiometabolic disease

The Microbiota and the Gut–Brain Axis in Controlling Food Intake and Energy Homeostasis

Interplay Between the Gut-Brain Axis, Obesity and Cognitive Function

The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity

Obesity and gut–microbiota–brain axis: A narrative review

Obesity and the gut microbiota: implications of neuroendocrine and immune signaling

Gut-brain axis: A matter of health and disease in neuropsychiatric disorders…!

Gut-brain axis: A matter of concern in neuropsychiatric disorders ...!

The microbiome-gut-brain axis in nutritional neuroscience

The Role of the Gut Microbiome in Energy Balance With a Focus on the Gut-Adipose Tissue Axis

Is the Gut Microbiota a New Factor Contributing to Obesity and Its Metabolic Disorders?

The Gut–Brain Axis in the Neuropsychological Disease Model of Obesity: A Classical Movie Revised by the Emerging Director “Microbiome”

The microbiome's influence on obesity: mechanisms and therapeutic potential

Dysbiotic Gut Bacteria in Obesity: An Overview of the Metabolic Mechanisms and Therapeutic Perspectives of Next-Generation Probiotics

The Microbiota-Gut-Brain Axis.

The gut microbiota in obesity and weight management: microbes as friends or foe?

The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities

Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities